Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. assyst

ASSYSt SIGNED

A reliable CXCL4 biomarker assay to improve diagnosis and treatment of Systemic Sclerosis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ASSYSt project word cloud

Explore the words cloud of the ASSYSt project. It provides you a very rough idea of what is the project "ASSYSt" about.

therapeutic    disorder    medical    predict    accessible    team    systemic    multiple    central    tool    culminating    cohorts    storage    argue    tract    excessive    cxcl4    curative    assessing    ultimately    chemokine    exacerbated    starting    fibrosis    fast    prevention    diagnosis    experiments    sensitive    guide    labs    pathogenesis    circulating    scleroderma    unclear    matrix    treatments    cheap    complications    lack    adequately    molecular    strategy    grant    decision    tissue    biomarker    aetiology    organ    deposition    disease    clinical    sclerosis    half    assay    internal    demonstrated    complement    levels    of    listed    heart    skin    lacking    extracellular    course    prognosis    diagnostic    suggest    player    collection    scarring    assyst    joints    assist    validate    complicates    ssc    lung    erc    treatment    organs    accelerate    patients    irrespective    business    measuring    replication    market    strategies    outcome    markers    autoimmune    prohibits    circumvent    gastrointestinal    protocols    kidneys    route    vitro    die   

Project "ASSYSt" data sheet

The following table provides information about the project.

Coordinator		 UNIVERSITAIR MEDISCH CENTRUM UTRECHT 

Organization address
address: HEIDELBERGLAAN 100
city: UTRECHT
postcode: 3584 CX
website: www.umcutrecht.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Netherlands [NL]
 Total cost 150˙000 €
 EC max contribution 150˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2017-PoC
 Funding Scheme ERC-POC
 Starting year 2018
 Duration (year-month-day) from 2018-08-01   to  2020-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITAIR MEDISCH CENTRUM UTRECHT NL (UTRECHT) coordinator 150˙000.00

Map

 Project objective

Systemic Sclerosis (SSc, scleroderma) is a complex autoimmune disorder of unclear aetiology, culminating in excessive extracellular matrix deposition (fibrosis/tissue scarring) in skin and internal organs (e.g. joints, heart, lung, gastrointestinal tract and kidneys). More than half of the patients will ultimately die as a result of organ complications. The medical need is exacerbated by the lack of curative treatments and the lack of specific and sensitive molecular markers to facilitate reliable diagnosis and prognosis.

My team has recently demonstrated, through research funded by the ERC Starting Grant CIRCUMVENT, that the chemokine CXCL4 is a central player in the pathogenesis of SSc. Our results suggest that CXCL4 has great potential as 1) a biomarker to assist early diagnosis, 2) a biomarker to predict SSc disease course, and 3) a therapeutic target for the treatment or prevention of fibrosis in patients with SSc. Currently, a robust, accessible, reliable, cheap and fast assay to determine CXCL4 levels for clinical use is lacking. This prohibits the use of CXCL4 to predict clinical and treatment outcome and complicates the large-scale replication experiments across multiple labs and cohorts that are necessary to validate the diagnostic value of CXCL4.

Therefore, we argue that a reliable in vitro assay measuring circulating CXCL4 levels is highly needed and can be deployed as a research support tool to accelerate the implementation of clinical strategies based on CXCL4 and a clinical decision support tool in SSc to complement current diagnostic protocols. ASSYSt will focus on 1) the development of a reliable assay to adequately determine circulating CXCL4 levels irrespective of sample collection and storage conditions, 2) assessing the market potential of each of the applications listed above, and 3) defining a strong business strategy to guide route to market.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ASSYST" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ASSYST" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

evolSingleCellGRN (2019)

Constraint, Adaptation, and Heterogeneity: Genomic and single-cell approaches to understanding the evolution of developmental gene regulatory networks

Read More  

IMMUNOTHROMBOSIS (2019)

Cross-talk between platelets and immunity - implications for host homeostasis and defense

Read More  

RODRESET (2019)

Development of novel optogenetic approaches for improving vision in macular degeneration

Read More